Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12; 113(11):2386-93.
Provan D, Stasi R, Newland AC,et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86.
Hamidpour M, Behrendt M, Griffiths B, Partridge L, Lindsey N. The isolation and characterization of antiplatelet antibodies. Eur J Haematol. 2006 Apr;76(4):331-8.
McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol. 2003 Dec;25 Suppl 1:S57-61
Fischer P, Jendreyko N, Hoffmann M, et al. Platelet reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. BrJ Haematol 1999; 105:626-640.
Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol. 2005 Feb; 81(2): 106-12.
Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein Ilb- IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001; 98: 130-139.
Filion MC, Proulx C, Bradley AJ, et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow derived cells. Blood 1996; 88: 2144-2150
Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIblllalpha versus GPIb alpha antibodies. Blood. 2006 Aug l;108(3):943-6
Louwes H, Zeinali Lathori OA, Vellenga E, et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999; 106:430-434.
Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003 Aug l;102(3):887-95.
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004 Feb 15;103(4):1364-9.
Calpin C, Dick P, Poon A et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? Arch Ped Adolesc Med 1998;152:345-7.
George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
Kiihne T, Imbach P, Bolton-Maggs PHB, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001;358:2122-5.
Edslev PW, Rosth0j S, Treutiger I, et al. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children. Br J Haematol 2007;138:513-6.
Lilleyman JS, on behalf of the Paediatric Haematology Forum of the British Society of Haematology. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child 1994;71:251-3.
Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1228—31.
Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science NY 2001; 291: 484-486
Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high- dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989-95.
Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344:703-7.
From the Centers for Disease Control and Prevention. Outbreak of hepatitis С associated with intravenous immunoglobulin administration—United States, October 1993-June 1994. JAMA. 1994 Aug 10;272(6):424-5.
Kahwaji J, Barker E, Pepkowitz, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009 Dec; 4(12): 1993-7.
van Hoff J, Ritchey AK. Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. J Pediatr 1988; 113:563-6.
Suarez CR, Rademaker D, Hasson A, et al. High-dose steroids in childhood acute idiopathic thrombocytopenia purpura. Am J Pediatr Hematol Oncol 1986;8:111-5.
Carcao MD, Zipursky A, Butchart S, et al. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998; 424:71-4.
Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; 193-5
Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-700.
Tarantino MD, Young G, Bertolone SJ, et al. Single dose of anti-D immune globulin at 75 mg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148 :489-94
Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7.
Taube, Т., Schmid, H., Reinhard, H., von Stackelberg, A., Henze, G. &Overberg, U.S. (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purura.
Wang, J., Wiley, J.M., Luddy, R., Greenberg, J., Feuerstein, M.A. Bussel, J.B.Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. Journal of Pediatrics,2005; 146, 217-221.